Heterocyclic compound
AssigneeAstellas Pharma Inc.
InventorsFumie Takahashi, Sunao Imada, Toru Asano, Yoshihiro Kozuki, Junko Maeda, Koji Kato, Hidehiko Fukahori, Masahiko Shiwaku
Life of this patent
Estimating the term…
Loading patent…
AssigneeAstellas Pharma Inc.
InventorsFumie Takahashi, Sunao Imada, Toru Asano, Yoshihiro Kozuki, Junko Maeda, Koji Kato, Hidehiko Fukahori, Masahiko Shiwaku
Estimating the term…
Provided is a novel compound which is an agent for treating rejection reactions in various organ transplantations, allergy diseases, autoimmune diseases, and hematologic tumor, and based on a PI3Kδ selective inhibitory action and/or an IL-2 production inhibitory action and/or a B cell proliferation inhibitory action (including an activation inhibitory action). The provided compound has a PI3Kδ selective inhibitory action, an IL-2 production inhibitory action, and/or a B cell proliferation inhibitory action, including an activation inhibitory action.
A compound of the formula (I) or a salt thereof:
Dependencies are inferred from the claim text.